热门资讯> 正文
CureVac BV报告第四季度业绩
2024-04-24 19:30
- CureVac BV press release (NASDAQ:CVAC): Q4 pre-tax loss was €86.5 million and €260.0 million for the three and twelve months ended December 31, 2023, compared to €128.7 million and €249.2 million in the same period of 2022.
- Revenue of €22.6M (+93.2% Y/Y).
- “We finished 2023 with a robust cash position of €402.5 million supported in Q4 by the recognition of a €15 million milestone from GSK for the start of the Phase 2 development of our joint seasonal flu program,” said Pierre Kemula, Chief Financial Officer of CureVac. “Going into 2024, we have had a strong focus on cost management and increased operational efficiency. Importantly, and despite the wind-down of the Pandemic Preparedness Agreement with the German government, these efforts enable us to extend our runway into the fourth quarter of 2025.”
More on CureVac BV
- CureVac: No Momentum In Sight
- CureVac, MD Anderson team up for cancer vaccines
- CureVac posts early efficacy results for GSK-partnered flu shot
- Seeking Alpha’s Quant Rating on CureVac BV
- Historical earnings data for CureVac BV
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
